MOREPENLAB2023-04-012023-06-30 MOREPENLAB2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member MOREPENLAB2023-04-012023-06-30in-bse-fin:OneOperatingExpenses02Member MOREPENLAB2023-04-012023-06-30in-bse-fin:OneOperatingExpenses03Member MOREPENLAB2023-04-012023-06-30in-bse-fin:OneOperatingExpenses04Member MOREPENLAB2023-06-30 MOREPENLAB2023-04-012023-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 500288 MOREPENLAB NOTLISTED Morepen Laboratories Limited Equity 2023-04-01 2024-03-31 2023-08-05 2023-07-29 INR Lakhs First quarter 11:15:00 14:15:00 2023-08-05 2023-08-05 Not applicable Single segment Pharmaceuticals 2023-04-01 2023-06-30 Unaudited Standalone 3691029000.00 20839000.00 3711868000.00 2000838000.00 326226000.00 26210000.00 410708000.00 2827000.00 48927000.00 679009000.00 3494745000.00 217123000.00 0.00 217123000.00 58623000.00 0.00 58623000.00 0.00 158500000.00 0.00 0.00 0.00 0.00 158500000.00 10943000.00 169443000.00 0.00 0.00 1022271000.00 2 0.31 0.31 0.00 0.00 0.31 0.31 1.'The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 05, 2023. A Limited review of the same has been carried out by the Statutory Auditors. 2.'Figures for the quarter ended March 31, 2023 are the balancing figures between audited figures in respect of the full financial year and the year to date figure up to the third quarter of the relevant financial year which were subjected to Limited Review by the Auditors. 3.'The Company is engaged in the Pharmaceutical Business Segment. Other Expenses 292928000.00 Power and Fuel 69233000.00 Selling and Distribution Expenses 276760000.00 Travelling Expenses 40088000.00 Item that will not be reclassified to profit & Loss 14990000.00 14990000.00 4047000.00